Astrazeneca and Pieris team to develop mAb-like drugs for lung diseases

By Gareth Macdonald contact

- Last updated on GMT

iStock/yodiyim
iStock/yodiyim

Related tags: Protein, Pharmacology, Erythropoietin

Astrazeneca has teamed up with Pieris Pharmaceuticals Inc to develop antibody like mini proteins for the treatment of lung diseases.

The collaboration will see Pieris advance its preclinical asthma candidate - PRS-060 - into a Phase I clinical trial this year. If the study is successful, Astrazeneca will fund subsequent clinical development and commercialization.

PRS-060 is an anticalin, which are engineered versions of human lipocalins. They are similar to monoclonal antibodies in that they bind cell surface proteins, however, they are much small which means they has the potential to treat diseases in difficult to reach locations.

The deal – which will see AstraZeneca pay $57.5m (€52.6m) upfront - also grants the Anglo-Swedish drug firm the right to develop four more of Pieris’ anticalins for the treatment of respiratory diseases.

In return, Pieris could receive development milestones and commercial payments of $2.1bn as well as tiered royalties on the sales of any potential products.

The deal comes a few months after Pieris teamed up with Servier to apply its anticalin technology to immunology-oncology.

Like the AstraZeneca deal, the agreement with Servier focused on one candidate – a PD-1 targeting checkpoint inhibitor called PRS-332 – but also granted the firm rights to other candidates in Pieris’ pipeline.

Deals

The agreement with Astrazeneca is Pieris' third this year.

In February​, Pieris also licensed an option to commercialize its anaemia candidate and EPO rival, PRS-080, in Japan to Aska Pharmaceutical Co. Ltd.

PRS-080 is also an anticalin. It inhibits hepcidin, a polypeptide regulator of the iron metabolism. An excess of the protein in patients with kidney disease prevents iron uptake.

The idea is that PRS-080 is used to treat anaemia in kidney disease patients an alternative to current therapies like high dose erythropoietin stimulating medicines. 

Related news

Related products

show more

Removing Aggregates of an Acidic Monoclonal Antibody

Removing Aggregates of an Acidic Monoclonal Antibody

Bio-Rad Laboratories | 22-Oct-2018 | Technical / White Paper

CHT Ceramic Hydroxyapatite Media/Resins are known as the industry gold standard for
impurity removal during monoclonal antibody (mAb) purification....

Single-Step Influenza and Dengue Virus Purification

Single-Step Influenza and Dengue Virus Purification

Bio-Rad Laboratories | 08-Oct-2018 | Application Note

CHT XT is the newest addition to the CHT family of media. It has been designed for superior physical robustness to ensure it can be used repeatedly over...

Related suppliers

Follow us

Products

View more

Webinars